Major pharmaceutical companies are predicted to lose their footing in the urological disorders market by 2017, a new report by pharmaceutical intelligence expert GBI Research has found.
The new report revealed that the global urological disorders market will witness multiple patent expiries between 2009 and 2017.
They include several of the top-selling blockbuster drugs in the urinary incontinence (UI), benign prostatic hyperplasia (BPH), urinary tract Infection (UTI) and interstitial cystitis (IC) markets.
To read the latest edition of Healthcare Global, click here
- Watchdog approves Vinnie Jones’ hands-only CPR ad
- 30 second eye test could help prevent heart attacks
- New plasma flashlight can kill bacteria and germs
Such patent expirations of leading drugs are expected to erode the 72 percent market share held in 2010 by the top five players in the field, namely Johnson & Johnson, Boehringer Ingelheim, Astellas Pharma, Pfizer, and GlaxoSmithKline (GSK).
Important drugs that have recently lost patent protection include Boehringer Ingelheim and Astellas Pharma’s Flomax (tamsulosin) in 2009 and Johnson & Johnson’s Levaquin (levofloxacin) in 2010.
Drugs set to lose patent protection in the coming years include, Pfizer’s Detrol (tolterodine) in Septemeber 2012, Johnson & Johnson’s Doribax in 2015 and Glaxosmithkline’s Avodart in 2015.
The current urological disorders pipeline does offer some promising novel products, namely URG101, YM178, NX-1207, PRX302 and PSD597, indicated for different segments of the market.
However, revenue generated from these products is not expected to balance revenue losses incurred from patent expiries, and the market is expected to show slow growth in the forecast period.
Mergers and acquisitions have become popular in the urological disorders market, with increased participation from smaller companies able to rival leading corporations through co-operating with one another.
This has led to the decline experienced in recent years by 2010 market leaders Johnson & Johnson and Pfizer.
The global urological disorders market was estimated to be worth $8.1 billion in 2010, following a Compound Annual Growth Rate (CAGR) of 7.9 percent during 2002-2010, and is forecast to increase at a lower CAGR of 3.4 percent in the future to exceed $10 billion by 2017.
The Healthcare Global magazine is now available on the iPad. Click here to download it.